4/A: Immunic Inc. Executive Chairman Duane Nash Amends Stock Option Filing

Executive Chairman of Immunic Inc., Duane Nash, files an amendment to a previous Form 4 to correct the vesting schedule of a stock option grant.

Summary

• Duane Nash, Executive Chairman of Immunic Inc., filed an amended Form 4 to correct the vesting schedule of a stock option grant.
• The original Form 4 was filed on December 6, 2024, and this amendment was filed on December 9, 2024.
• The amendment corrects the vesting schedule of a stock option for 300,000 shares granted on December 4, 2024.
• The stock option has an exercise price of $1.25 and expires on December 4, 2034.
• The option vests in monthly increments over a period of one year from the grant date.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error, which is neither positive nor negative, but necessary for compliance. The sentiment is neutral to slightly positive as it shows attention to detail.

Industry Context

This is a standard regulatory filing related to stock options granted to company executives, which is common practice in publicly traded companies.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in publicly traded companies, such as Immunic Inc.
• The vesting schedule of monthly increments over one year is a typical vesting structure for stock options.
• The exercise price of $1.25 is specific to Immunic Inc. and would need to be compared to other similar companies to assess its relative value.

Stakeholder Impact

• The correction of the vesting schedule ensures accurate reporting to shareholders and the public.

Key Dates

Keywords

stock option, Form 4, amendment, vesting schedule, Immunic Inc., Duane Nash, executive chairman, insider trading